Pre-Symposium Welcome Reception

Boston Healthcare invites attendees to join them for a complimentary welcome reception at the symposium venue - Enjoy networking and collaboration opportunities, food and beverages in a relaxed atmosphere.

3:30-5:30 Symposium Registration & Pre-Welcome Reception  (Conference Level Foyer) 


8:00 Registration, Morning Coffee and Networking 

9:00 Chairperson’s Welcoming Remarks and Symposium Overview
A brief overview of NGS issues areas/dynamics in oncology and sharing of the key questions for the day.

Morning Session: Clinician/Provider Perspectives

9:10 Translating Genomics towards Implementation of Precision Medicine
Insights into the design of a multiplex panel NGS service offering, rationale behind development, and a sense of how it is being used to inform clinical care will be discussed.
Shashikant Kulkarni, Ph.D., FACMG, Director, Cytogenomics and Molecular Pathology Program Director, Clinical Genomics Fellowship Program; Associate Professor, Pathology & Immunology, Pediatrics and Genetics, Washington University School of Medicine 

9:40 Influence of NGS on Delivery of Care within a Pathway Program/Medical Home Facility
Discussion of the potential value-add of incorporating molecular diagnostic therapy selection tools to a pathway program used in a medical home facility.
Robert E. Baird, Jr., RN, MSA, CASC, CEO, Dayton Physicians Network 

10:10 Coffee Break and Networking 

Morning Session: Interactive Workshop

10:30 Turning Promise of NGS into Clinical Reality
The audience is sorted into 10 groups/tables. Moderator asks all tables the same challenge question. Group discussions occur for 20 mins then a representative from each table is asked to share a quick summary of their answers for 10 min (1 minute each). These comments are captured on PowerPoint slides that are updated and shown to the audience:

  • What is your vision of the future state in which NGS is successfully incorporated into clinical practice?
  • What can be done to address the issues/barriers to adoption of NGS in clinical practice?

Morning Session: Clinician/Provider Perspectives (cont’d)

11:30 Influence of NGS Information on Clinical Decision-Making/Practice
The impact of having NGS information for clinical care decision-making, particularly around selection of therapies for patients, will be shared from the perspective of a thought-leading KOL/ oncologist.
Douglas B. Johnson, M.D., MSCI, Assistant Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center 

12:00 pm Lunch and Networking 

Afternoon Session: Pathways to Identifying Clinical and Health Economic Impact

1:15 Chairperson’s Remarks 

1:20 Viewpoints of the Marketplace of an NGS Platform Player
The interest in the development of clinical applications of NGS and the preliminary feedback from the marketplace on the value-add when a laboratorian creates an NGS offering will be discussed.
Paul R. Billings, M.D., Ph.D., Chief Medical Officer (consulting), Thermo Fisher Scientific 

1:50 NGS: Next-Generation Strategies for Clinical Sequencing
The promise of Precision Medicine is becoming reality with the increase in targeted therapies and companion diagnostics. Next-Generation sequencing offers a multiplex solution to solve some of the diagnostic challenges such as a simplification of the workflow and ensuring all relevant biomarkers are assessed. These opportunities also represent potential hurdles in the commercial implementation in today’s world and in this talk we highlight some of the challenges that will need to be overcome.
Jonathan Pan, Ph.D., MBA, Director, Oncology Companion Diagnostics and Disease Strategy, GlaxoSmithKline 

2:20 Payer Perspective on Clinical Applications and Economics
A summation of thoughts about the potential benefits and drawbacks of the on-going application of NGS in clinical practice. Specific discussions about possible means/best practices for identifying and articulating the clinical utility and health economic impact of the tool
Michael Kolodziej, M.D., National Medical Director, Oncology Strategy, Aetna 

2:50 Validity and Utility for NGS-Based Oncology Panels
Payer coverage and reimbursement decisions for molecular diagnostic tests generally depend on evaluation of the analytical validity, clinical validity, and clinical utility. However, stakeholder perspectives on various aspects of these seemingly simple concepts, including (but not limited to) evidentiary standards and pricing, often differ, and constitute arguably the most intractable challenge to the progress of personalized medicine. In this session, we will review potential solutions in the context of next-generation sequencing-based testing in oncology. 
Girish Putcha, M.D., Ph.D., Director, Laboratory Science, Palmetto GBA; Founding Medical Director, Orion Genomics and TOMA Biosciences 

3:20 Refreshment Break and Networking 

Afternoon Session: Panel Discussion

3:50 The Economics of NGS and Market Solutions
A panel comprised of several of the speakers from earlier in the day (payer, platform player, clinician/provider) the moderator and audience ask questions which prompt discussion around the following topics/questions:

  • Strength and weaknesses of current approaches
  • Clinical and economic information gaps and possible means to address them
  • Anticipated risks and solutions
  • Trends moving forward

4:50 Closing Remarks 

5:00 Close of Symposium